Brief: AB Science Granted Authorization By ANSM To Initiate Confirmatory Phase III Trial Of Masitinib In Progressive Forms Of Multiple Sclerosis
03/01/2022 17:19
Jan 3 (Reuters) - AB Science SA ABS.PA :
* GRANTED AUTHORIZATION TO INITIATE CONFIRMATORY PHASE III
TRIAL
OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS BY THE
FRENCH HEALTH AUTHORITY (ANSM)
* STUDY WILL ENROLL 800 PATIENTS FROM NUMEROUS STUDY CENTERS
* PRIMARY OBJECTIVE OF STUDY WILL BE TO EVALUATE EFFECT OF
MASITINIB ON TIME TO CONFIRMED DISABILITY PROGRESSION
Source text for Eikon: ID:nGNE82mvvR
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease